ABOUT
The Swedish-American Life Science Summit 2012
The Swedish-American Life Science Summit 2012 is the eight in a
series of summits, in an invitation-only format where we present a
program featuring some of the best known Life Science executives and
investors in the world.
The intense and exclusive two-day program includes high-level panel
discussions, insights from keynote speakers as well as a few selected
presentations by successful and promising Swedish companies.
It is our hope and ambition that the summit will serve to increase the
amount of cross-border business between the largest market in the
world, the United States, and one of the most important Life Science
industry centers in Europe, Sweden.
In addition, over the last couple of years the summit has taken on an
increasingly global nature, making the summit a true reflection of the
Life Science industry today.
Chairman & Senior Advisory Board
The people behind the Swedish-American Life Science Summit combine a long experience in the US pharmaceutical industry and Wall Street with today’s financial services within the field of Life Science in both countries.
Chairman
Barbro C. Ehnbom has been a pioneer in the Life
Science industry throughout her whole career. She was one of the first
female executives in several US pharmaceutical companies, a top analyst
in Wall Street, followed by many years of investment banking. As a long
time board member of the Swedish-American Chamber of Commerce and
Chairman Emeritus of the Swedish Economist Group in New York, she has
30 years experience in organizing events between Sweden and the U.S.,
not only in the commercial field but also in academics, music, the arts
and social entrepreneurship.
View Curriculum
Vitae »
View article
from Dagens Industri (pdf, 90Kb) »
Learn more
about The Female Economist of the Year Scholarship »
Senior Advisor
Frederick Frank is Vice Chairman of Peter J.
Solomon Company. Mr. Frank brings to the summit over forty-five years
of experience. Before joining Peter J. Solomon Company Mr. Frank was
Vice Chairman of Lehman Brothers and Barclays Capital. Prior to joining
Lehman Brothers he was Director of research and a Director of Smith,
Barney & Co. Inc. He serves on the Board of Directors of several
public companies and has provided investment banking services to an
extensive number of companies in the pharmaceutical, biotechnology,
healthcare service providers, medical device and nutraceutical
industries, and has been involved in hundreds of financings and merger
and acquisition transactions in the global health care industry.
View article from Biotech Sweden
(hi-res jpg, 2Mb) »
Senior Advisor
Dr. Hans Wigzell , MD, Ph. D. is Professor emeritus
in Immunology at the Department of Microbiology, Tumour and Cell
Biology at Karolinska Institutet since 2005. He is Chairman of
Karolinska Development AB and board member of Swedish Orphan Biovitrum
and a member of the Royal Swedish Academy of Sciences and the Royal
Swedish Academy of Engineering Sciences. Dr. Wigzell was the President
of Karolinska Institutet 1995-2003. From 1986 to 1991 he was head of
first the National Bacteriological Laboratory and then its successor
Swedish Institute for Infectious Disease Control. He is a member of the
Board of the Karolinska Development AB (Chairman), RaySearch AB,
Humabs, Intercell AG and AVIBiopharma as well as Chairman of Stockholm
School of Entrepreneurship.
Senior Advisor
Dr. Karin Hehenberger , has served as Senior Vice President at Coronado Biosciences since December 2011 and has over 15 years of experience in the healthcare industry. Most recently, Dr. Hehenberger was Senior Vice President for Strategic Alliances at the Juvenile Diabetes Research Foundation (JDRF). She was responsible for advancing the JDRF's involvement with scientific, financial, and commercial partners in the diabetes community. Prior to JDRF, Dr. Hehenberger worked at Johnson & Johnson as Vice President of Metabolic Strategy and Business Development. Dr. Hehenberger also has experience in public and private equity, having been a partner in Scandinavian Life Science Venture, a buy-side healthcare equity analyst at Brummer & Partners and Argus Partners, on the senior management team of Eyetech Pharmaceuticals, and earlier in her career as a strategic management consultant at McKinsey & Co. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a JDRF post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School.
Senior Advisor
G. Steven Burrill is the Chief Executive Officer at Burrill & Company that is a diversified global financial services firm focused on the life sciences industry. G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves on the Boards of Directors of AliveCor, Catalyst Biosciences, Depomed (NASDAQ: DEPO), NewBridge, Novadaq (TSX: NDQ), Proventys, Targacept (NASDAQ: TRGT) and XDx. Previously he served as Chairman of the Boards of BioImagene, Abunda Nutrition and Pharmasset. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.
Program Advisor
Program Advisor
Lena Tibell is Founder & Managing Partner of
Tibell & Associates, a consultancy firm within Life Science
Business Management. She has over 20 years experience of International
Sales & Marketing and Business Management in Life Science industry
plus 10 years in Medical research and Drug analysis. Her experience
covers Business Strategies, Market Assessments, Product Development and
Launch, as well as Clinical Evaluations. Lena has senior competence in
working with Distributors and Sales organizations, as well as
Starting-up and Re-organizing sales companies. Prior to starting Tibell
& Associates, she held positions as Business Manager at Hudson RCI
and Louis Gibeck, Marketing Manager at Pharmacia Biotech and Clinical
Development Engineer at a Swedish University Hospital.
Administration SALSS 2012
Project Manager
Sana Alajmovic holds a Bachelor of Science (BSc) in Business and Economics from Stockholm School of Economics (SSE). Prior to becoming Project Manager for SALSS 2012, Sana worked as an Assistant Events & Marketing Manager at the Swedish-American Chamber of Commerce in New York. Previously, she was Managing Director at the venture capital firm Curitas within the Procuritas Group and Operations Manager for the charity foundation Chelha in Stockholm. She has different internship experiences in marketing at Oriflame in Istanbul as well as in management consulting. Sana has conducted studies in philosophy at Stockholm University and literature at University of Cambridge, UK and has managed and led several international projects in Bosnia and Herzegovina, Japan and the United Arab Emirates.
Technical Administrator
Linda Svensson is a Master student in Biochemistry and is currently studying at the school of Entrepreneurship at Uppsala University. During the year of 2011 she was President of the Student Union at Linköpings University and finalist for the best Swedish student leadership. Linda is part Brazilian and has improved her skills in Portuguese during studies in Portugal.
